Could AI save us from the next pandemic?

The COVID-19 pandemic was an eye opener for the world on how quickly diseases and pathogens can emerge and spread globally, wreaking havoc on societies, economies, and healthcare systems. While the pharmaceutical industry scrambled for vaccines and treatments for COVID-19, AI could give us the edge over the next global health threat, says Jeremy Skillington, PhD, CEO of Poolbeg Pharma.

Unfortunately, we’re living in a time where it’s not a matter of if, but when the next new pandemic will hit. This is driven by a number of factors like globalisation and climate change. We know viruses are constantly mutating through the process of evolution and natural selection, with the risk that a virus could spread from one species to another. And with factors like climate change, for example, we know that humans are coming into closer contact with animals as we encroach into their habitats. This proximity increases the likelihood of zoonotic diseases, which are infections transmitted from animals to humans.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Poolbeg Pharma

More articles like this

Poolbeg Pharma’s Cathal Friel assumes role of Executive Chairman

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced a change of Board role and the Remuneration Committee’s approval of

What will cancer therapy look like in 2034?

Drugs like PARP inhibitors and chimeric antigen receptor (CAR) therapies, and advancements in artificial intelligence in drug discovery, have spurred hope for improved cancer care in the past year. Rigorous research has paved the way for a

Reducing cancer immunotherapy-induced CRS

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.